The clinical trial investigates the efficacy and safety of Tislelizumab, a PD-1 inhibitor, in combination with chemotherapy agents (Cyclophosphamide, Mitoxantrone Liposomes) and epigenetic regulators (Chidamide, Prednisone) for treating relapsed/refractory Angioimmunoblastic T-Cell Lymphoma (AITL). Given the aggressive nature of AITL and the limited treatment options available, successful outcomes could position Tislelizumab as a significant therapeutic option in a niche market. The trial is currently recruiting in China, indicating a potential first-mover advantage in this indication. However, the competitive landscape includes other PD-1/PD-L1 inhibitors and emerging therapies targeting similar patient populations, necessitating ongoing diligence on market dynamics and competitor developments.